Cargando…
Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction
(1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) and heart failure with a preserved ejection fraction (HFpEF). Monocytes and T-helpers (Th) are involved in both pro-inflammatory and fibrotic processes, while re...
Autores principales: | Ovchinnikov, Artem, Filatova, Anastasiya, Potekhina, Alexandra, Arefieva, Tatiana, Gvozdeva, Anna, Ageev, Fail, Belyavskiy, Evgeny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380876/ https://www.ncbi.nlm.nih.gov/pubmed/37504566 http://dx.doi.org/10.3390/jcdd10070310 |
Ejemplares similares
-
Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022) -
Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study
por: Ovchinnikov, Artem, et al.
Publicado: (2022) -
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study
por: Belyavskiy, Evgeny, et al.
Publicado: (2020) -
The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction
por: Ovchinnikov, A. G., et al.
Publicado: (2020) -
Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction
por: Garg, Pankaj, et al.
Publicado: (2021)